SAN DIEGO, April 01, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 27,000 shares of its common stock to four new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive…

SAN DIEGO, March 03, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021. The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in…

SAN DIEGO, Feb. 25, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months and full year ended December 31, 2020 and provided an update on its corporate activities and product pipeline. "We are pleased with our progress across our rezafungin Phase 3 trials and Cloudbreak platforms despite the…

New analyses from completed Phase 2 STRIVE trial support once-weekly, long-acting rezafungin for the treatment of candidemia and invasive candidiasis in high-risk patient populationsSAN DIEGO, Feb. 17, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced data from three posters at the 21st International Immunocompromised Host Society (ICHS) Symposium on Infections in the Immunocompromised…

SAN DIEGO, Feb. 11, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced an oral presentation and four poster presentations at the 21st International Immunocompromised Host Society (ICHS) Symposium on Infections in the Immunocompromised Host, taking place virtually Feb. 17-19, 2021. Cidara will share new findings related to rezafungin, its novel once-weekly echinocandin in…

SAN DIEGO, Jan. 25, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of internationally-renowned molecular biologist Bonnie Bassler, Ph.D., and seasoned life science executive Carin Canale-Theakston to its board of directors. "We are pleased to welcome Dr. Bassler and Ms. Canale-Theakston to our board of directors," said Jeffrey Stein, Ph.D., president…

SAN DIEGO, Jan. 05, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted a stock option to purchase 115,000 shares of its common stock to a new employee, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of December…

Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara's antifungal and antiviral programsSAN DIEGO, Dec. 15, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of…

SAN DIEGO, Dec. 01, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced a keynote lecture, an oral presentation and two posters at the 7th European Scientific Working Group on Influenza (ESWI) Influenza Conference, which takes place virtually Dec. 6-9, 2020. The Keynote Lecture highlights Cidara's Cloudbreak antiviral platform, specifically its program for universal…

SAN DIEGO, Nov. 30, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at European Society of Intensive Care Medicine (ESICM) LIVES 2020, which takes place virtually Dec. 6-9, 2020. Cidara will highlight analyses from the completed Phase 2 STRIVE trial of rezafungin for treatment of candidemia and/or…